1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Baseline characteristics of the 56 patients of the study
CharacteristicsValue
Age (yr) (median) (Q1–Q3)54 (46–66)
Female (No.) (%)51 (92)
Vascular risk factor (No.) (%)31 (55)
Antiaggregation platelet therapy (No.) (%)15 (27)
Asymptomatic (No.) (%)4 (7)
Pain (No.) (%)43 (77)
Cranial nerve palsy (No.) (%)40 (72)
SAH or CCF (No.) (%)4 (7)
Giant saccular aneurysms (≥25 mm) (No.) (%)27 (48)
Large saccular aneurysms (≥15 mm, <25) (No.) (%)24 (43)
Fusiform aneurysms (No.) (%)5 (9)
Infraclinoid aneurysms (No.) (%)42 (75)
Mural thrombus (No.) (%)15 (27)
Multiple aneurysms (No.) (%)11 (20)
Timing of BOT ≥2 sec (No.) (%)7 (13)
General anesthesia (No.) (%)16 (28)
  • Note:—CCF indicates carotid cavernous fistula.